NO20020031L - Dihydrobenzodiazepiner og deres anvendelse til behandling av dyslipidemi - Google Patents

Dihydrobenzodiazepiner og deres anvendelse til behandling av dyslipidemi

Info

Publication number
NO20020031L
NO20020031L NO20020031A NO20020031A NO20020031L NO 20020031 L NO20020031 L NO 20020031L NO 20020031 A NO20020031 A NO 20020031A NO 20020031 A NO20020031 A NO 20020031A NO 20020031 L NO20020031 L NO 20020031L
Authority
NO
Norway
Prior art keywords
dyslipidemia
treatment
dihydrobenzodiazepines
atherosclerosis
complications
Prior art date
Application number
NO20020031A
Other languages
English (en)
Other versions
NO20020031D0 (no
Inventor
Jean-Jacques Berthelon
Daniel Guerrier
Michel Brunet
Jean-Jacques Zeiller
Francis Contard
Frederic Ausseil
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20020031D0 publication Critical patent/NO20020031D0/no
Publication of NO20020031L publication Critical patent/NO20020031L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/04—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/46—Doubly bound oxygen atoms, or two oxygen atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Oppfinnelsen vedrører benzo-diazepinderivater med formel (I). og deres anvendelse til behandling av dyslipidemi, aterosklerose, sukkersyke og dens komplikasjoner.
NO20020031A 1999-07-06 2002-01-04 Dihydrobenzodiazepiner og deres anvendelse til behandling av dyslipidemi NO20020031L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9908714A FR2796070B1 (fr) 1999-07-06 1999-07-06 Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
PCT/EP2000/006230 WO2001002373A1 (fr) 1999-07-06 2000-07-04 Dihydrobenzodiazepines et leur utilisation dans le traitement de dyslipidemies

Publications (2)

Publication Number Publication Date
NO20020031D0 NO20020031D0 (no) 2002-01-04
NO20020031L true NO20020031L (no) 2002-03-05

Family

ID=9547763

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020031A NO20020031L (no) 1999-07-06 2002-01-04 Dihydrobenzodiazepiner og deres anvendelse til behandling av dyslipidemi

Country Status (22)

Country Link
US (1) US7323458B1 (no)
EP (1) EP1189890B1 (no)
JP (1) JP4699663B2 (no)
KR (1) KR20020022763A (no)
CN (1) CN1359377A (no)
AR (1) AR031071A1 (no)
AT (1) ATE323685T1 (no)
AU (1) AU767016B2 (no)
BR (1) BR0012169A (no)
CA (1) CA2378165C (no)
CZ (1) CZ20014604A3 (no)
DE (1) DE60027429T2 (no)
ES (1) ES2258975T3 (no)
FR (1) FR2796070B1 (no)
HU (1) HUP0201785A3 (no)
MX (1) MXPA01013457A (no)
NO (1) NO20020031L (no)
PL (1) PL352333A1 (no)
RU (1) RU2247115C2 (no)
SK (1) SK19142001A3 (no)
WO (1) WO2001002373A1 (no)
ZA (1) ZA200201008B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10142660A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von Derivaten von C2-substituierten Indan-1-ol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US6677303B2 (en) * 2001-04-30 2004-01-13 Syn X Pharma Biopolymer marker indicative of disease state having a molecular weight of 1097 daltons
ATE408593T1 (de) * 2001-05-03 2008-10-15 Galileo Lab Inc Pyruvatderivate
DE10142668A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142659A1 (de) 2001-08-31 2003-03-20 Aventis Pharma Gmbh Verwendung von mehrfach substituierten Indan-1-ol. Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE10142722A1 (de) * 2001-08-31 2003-03-27 Aventis Pharma Deutschland GmbH, 65929 Frankfurt C2-substituierte Indan-1-one und ihre Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE10320732A1 (de) * 2003-05-05 2004-12-09 Friedrich-Schiller-Universität Jena Büro für Forschungstransfer Neue schnell wirkende Anästhetika und Verfahren zu ihrer Herstellung
JP4832295B2 (ja) * 2003-07-10 2011-12-07 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー シトクロムｐ４５０阻害剤としてのナフタレン誘導体
AU2004259009A1 (en) * 2003-07-23 2005-02-03 Exelixis, Inc. Azepine derivatives as pharmaceutical agents
ZA200603515B (en) * 2003-10-08 2007-11-28 Vertex Pharma Modulators of ATP-binding cassette transporters
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
WO2006063294A2 (en) * 2004-12-09 2006-06-15 Kalypsys, Inc. Novel inhibitors of histone deacetylase for the treatment of disease
GB0506133D0 (en) * 2005-03-24 2005-05-04 Sterix Ltd Compound
KR102585191B1 (ko) * 2020-08-25 2023-10-04 경기대학교 산학협력단 신규한 벤조디아제핀-3-온 유도체 및 이를 포함하는 당뇨병성 신경병증 치료 또는 예방용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3780023A (en) * 1972-06-30 1973-12-18 J Suh 2-aralkylamino-4,5-dihydro-3h-1,3-benzodiazepines
ES484553A1 (es) 1978-10-05 1980-05-16 Hoechst Ag Un metodo para preparar 4-fenil-1,3-benzodiazepinas
US5260339A (en) 1978-10-05 1993-11-09 Hoechst-Roussel Pharmaceuticals Incorporated 4-phenyl-1,3-benzodiazepines and 2-amino-α-phenylphenethylamines for treating convulsions and protecting neurons
FR2540871B1 (fr) 1983-02-16 1986-01-10 Lipha Amino-2 phenyl-5 benzodiazepines-1,3; procede de preparation et medicaments les contenant
FR2550199B1 (fr) * 1983-08-02 1985-11-29 Lipha Imidazo et pyrimido (2,1-b) benzodiazepines-1,3, procedes de preparation et medicament les contenant
ZA956647B (en) * 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.

Also Published As

Publication number Publication date
FR2796070A1 (fr) 2001-01-12
AU767016B2 (en) 2003-10-30
DE60027429T2 (de) 2006-12-14
CN1359377A (zh) 2002-07-17
AU5981400A (en) 2001-01-22
CA2378165A1 (en) 2001-01-11
BR0012169A (pt) 2002-03-19
US7323458B1 (en) 2008-01-29
ZA200201008B (en) 2003-08-27
MXPA01013457A (es) 2002-07-22
EP1189890B1 (fr) 2006-04-19
WO2001002373A1 (fr) 2001-01-11
KR20020022763A (ko) 2002-03-27
ES2258975T3 (es) 2006-09-16
ATE323685T1 (de) 2006-05-15
HUP0201785A2 (hu) 2002-12-28
JP2003503483A (ja) 2003-01-28
PL352333A1 (en) 2003-08-11
WO2001002373A8 (fr) 2001-06-14
DE60027429D1 (de) 2006-05-24
CA2378165C (en) 2010-08-17
NO20020031D0 (no) 2002-01-04
JP4699663B2 (ja) 2011-06-15
RU2247115C2 (ru) 2005-02-27
SK19142001A3 (sk) 2002-06-04
EP1189890A1 (fr) 2002-03-27
FR2796070B1 (fr) 2003-02-21
AR031071A1 (es) 2003-09-10
CZ20014604A3 (cs) 2002-08-14
HUP0201785A3 (en) 2003-02-28

Similar Documents

Publication Publication Date Title
NO20015156D0 (no) 5-pyridyl-1,3-Azol forbindelser, fremgangsmåte for produksjon av de samme og deres anvendelse
TR200103221T2 (tr) Heterosiklik olarak ikame edilmiş benzimidazoller, bunların üretimi ve uygulanması
WO2001066564A3 (en) Gamma-secretase inhibitors
NO20020031L (no) Dihydrobenzodiazepiner og deres anvendelse til behandling av dyslipidemi
NO20021379L (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
YU21401A (sh) Tetrahidropiridoetri
NO20052796L (no) Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
NO20030301L (no) Nye heteroarylderivater og anvendelse derav som farmasöytika
NO20003233D0 (no) 4-hydrokykinolin-3-karboksamider og hydraziner som antivirale midler
NO20081434L (no) 5-(fenylisoksazolyletoksy)-triazol-3-yl substituert pyridinsammensetninger for behandling av neurologisk, psykiatrisk eller smerteforstyrrelser
WO2002046171A3 (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
PT1347971E (pt) Inibidores tiazolilicos de tirosina-cinases da familia tec
TR200103493T2 (tr) Metaloproteaz önleyicileri
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
WO2003005999A8 (en) Methods of treating cytokine mediated diseases
IL151313A0 (en) Lipase containing pharmaceutical compositions
NO20024775D0 (no) Hydroksyfenyl-piperidin-4-yliden-metyl-benzamidderivater til behandling av smerte
NO20016149D0 (no) Indol-derivater og deres anvendelse for behandling av osteporose blant andre applikasjoner
DE60045010D1 (de) Behandlung von infektionen des verdauungstrakts mit enzymen
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
NO20014314D0 (no) Blandinger og metoder for behandling av stafylokokkisk infeksjon
EP1319402A4 (en) IgE FORMATION INHIBITORS
DE60310767D1 (de) PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN
MXPA04004372A (es) Derivados heterociclicos de glicinamida y su uso medico.
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application